Previous 10 | Next 10 |
NEW YORK and LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicate...
Akari Therapeutics (AKTX) records the first quarterly net income in nearly five years as the company announces financial results for Q3 2020.Recording ~$1.4M of net income (compared to a net loss of ~$2.6M in the corresponding period in the prior year), the company is in the black f...
Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food and Drug Administration ( FDA) and European Medicines Agency (EMA) meetings earlier in...
New data accrued from 19 PNH patients treated for over 30 cumulative patient-years show that self-administered nomacopan is well-tolerated and substantially reduces transfusion dependence. Transfusion independence of 79% reported for 14 formerly transfusion dependent PNH patients ...
Akari Therapeutics ([[AKTX]] +12.9%) announces the publication of the results of a two-year research collaboration with the University College of London Institute of Ophthalmology, studying Akari’s lead drug candidate, nomacopan (formerly known as Coversin), a C5 complement inhibitor t...
New data highlight role of leukotriene B4 (LTB4) in the pathophysiology of retinal inflammation and degeneration I n the experimental allergic uveitis (EAU) disease model nomacopan reduce d Th17 effector T cell and macrophage activity in addition to known...
Safety and efficacy data from Phase II clinical trial of nomacopan in adults with mild to moderate BP The Phase II data was the basis for the agreement of the FDA and the EMA that Akari may proceed to a Phase III randomised placebo - controlled study usin g n...
Akari Therapeutics ([[AKTX]] -1.6%) announces further progress in its COVID-19 pneumonia program with nomacopan in the U.S. and Brazil.Nomacopan’s dual complement and leukotriene inhibition has applicability in a range of other severe lung inflammatory conditionsCOV...
FDA clearance received to proceed with investigator- led multi-center double blind randomized clinical study in the U . S . with nomacopan following prior expanded access program Following initial proof of principle stu...
Akari Therapeutics ([[AKTX]] -4.6%) completes a scientific advice meeting with the European Medicines Agency ((EMA)) prior to initiation of a Phase 3 study of nomacopan for the treatment of bullous pemphigoid ((BP)), a rare skin disorder characterized by large fluid-filled blisters on areas o...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...